ArticleJugan geon-gang gwa jilbyeong2023
[Current Status of Creutzfeldt-Jakob Disease in the Republic of Korea, 2017-2021].
Article in Jugan geon-gang gwa jilbyeong, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Creutzfeldt-Jakob disease (CJD) is transmitted by pathogenic substances called prions and can rapidly lead to death. However, no specialized treatment (medicine) has been developed to date. The route of infection is classified into sporadic (sCJD), iatrogenic, genetic forms (gCJD), and variant (vCJD). sCJD accounts for 85-90%, while gCJD accounts for 10-15%. CJD was managed through infectious disease surveillance based on the Infectious Disease Prevention and Control Act. In 2011, the monitoring method was changed to a total surveillance system. From 2017 to 2021, 276 patients had probable CJD in the Republic of Korea. Of the total cases, CJD was diagnosed in 35%, and the incidence was higher in patients aged 60-70 years. Of 276 patients, 150 were women (54.3%) and 126 were men (45.7%), with more women than men by 8.6%. For sCJD, the incidence was 92.6% higher in those aged ≥50 years than that in those <50 years old, and for gCJD, the incidence was 54.2% higher in those aged ≥50 years. Upon analysis of the incidence of cases by CJD type and age groups above 50 and under, a significant difference (p<0.05) was observed. From 2017 to 2021, the incidence of CJD by type was 87.0% for sCJD and 13.0% for gCJD, with an incidence of 0.1 per 100,000 people. There was no domestic occurrence of vCJD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.